Intellia therapeutics stock comprar ou vender
Get instant access to a free live interactive chart for the Intellia Therapeutics Inc stock. You have the option to change the appearance of the charts by varying the time scale, chart type, zooming in to different sections and adding new studies or indicators such as RSI, MACD, EMA, Bollinger Bands, Fibonacci retracements and many more. 18/04/2016 · Founded in 2014, Intellia Therapeutics has taken in $89 million in funding compared to the $210 million in funding Editas Medicine (NASDAQ:EDIT) took in prior to their IPO. Intellia filed for an IPO last week to raise $50 million compared to the $94.4 million Editas Medicine raised in their recent IPO. 08/11/2019 · NTLA, Intellia Therapeutics - Stock quote performance, technical chart analysis, SmartSelect Ratings, Group Leaders and the latest company headlines Intellia Therapeutics (NTLA) - DEVELOPS THERAPEUTICS USING A BIOLOGICAL TOOL KNOWN AS CRISPR/CAS9 SYSTEM TO TREAT GENE-ASSOCIATED DISEASES. Cara Therapeutics A Cara Therapeutics Inc. foi fundada em 2004 e tem sede em Stamford, no Connecticut. Esta empresa de biotecnologia desenvolve e comercializa soluções farmacêuticas, sobretudo para alívio da dor do sistema nervoso periférico pela estimulação seletiva dos recetores opióides capa periféricos do corpo. The latest Tweets from Intellia Therapeutics (@intelliatweets). Treating genetic disease at the cutting edge: Intellia is a CRISPR/Cas9 focused biotechnology company 27/10/2019 · 7 Wall Street analysts have issued ratings and price targets for Intellia Therapeutics in the last 12 months. Their average twelve-month price target is $26.92, suggesting that the stock has a possible upside of 78.85%. The high price target for NTLA …
The latest Tweets from Intellia Therapeutics (@intelliatweets). Treating genetic disease at the cutting edge: Intellia is a CRISPR/Cas9 focused biotechnology company
Real-time trade and investing ideas on Intellia Therapeutics NTLA from the largest community of traders and investors. ST Invest is a wholly owned subsidiary of StockTwits, Inc. Investing in securities products involves risk, including possible loss of principal. Intellia Therapeutics has a market cap of $756.20 M, which represents its current share price of $15.47 multiplied by its outstanding share number of 48.88. As a small-cap company, NTLA's shareholders are exposed to the most risk. The company's Market Capitalization is a measurement of company size. ⬇ Fazer download de Nyse fotografias de stock na melhor agência de fotografia de stock preços acessíveis milhões de fotografias de stock, imagens e desenhos premium de alta qualidade e … Free current stock price quotes and data for Intellia Therapeutics Inc (NTLA). Research news, charts, stock market performance and earnings. Intellia Therapeutics, Inc. (NTLA) Shares March Higher, Can It Continue? By Zacks Investment Research - Nov 06, 2019. As of late, it has definitely been a great time to be an investor in Intellia Therapeutics, Inc. (NASDAQ:NTLA) . The stock has moved higher by 22.5% in the past month, while it is also above its 20
Get instant access to a free live interactive chart for the Intellia Therapeutics Inc stock. You have the option to change the appearance of the charts by varying the time scale, chart type, zooming in to different sections and adding new studies or indicators such as RSI, MACD, EMA, Bollinger Bands, Fibonacci retracements and many more.
Intellia Therapeutics and the Intellia Therapeutics logo are registered trademarks with the U.S. Patent & Trademark Office. 20/09/2001 · Intellia Therapeutics, Inc. engages in the development of gene editing-based therapies. It provides scientific expertise, clinical development, and intellectual property position to unlock broad therapeutic applications of CRISPR or Cas9 genome editing and develop a potential new drug class. The 26/12/2019 · Discover historical prices for NTLA stock on Yahoo Finance. View daily, weekly or monthly format back to when Intellia Therapeutics, Inc. stock was issued. The all-time high Intellia Therapeutics stock closing price was 34.95 on March 09, 2018. The Intellia Therapeutics 52-week high stock price is 19.00, which is 20.1% above the current share price. The Intellia Therapeutics 52-week low stock price is 10.26, which is 35.1% below the current share price.
Intellia Therapeutics Inc Intellia Therapeutics Inc. (formerly known as AZRN Inc.) was founded in 2014 and is headquartered in Cambridge, Massachusetts. The company is currently focused on gene editing and the development of therapeutics based on a unique biological tool called CRISPR/Cas9 system.
In depth view into NTLA (Intellia Therapeutics) stock including the latest price, news, dividend history, earnings information and financials. Get breaking news and analysis on Intellia Therapeutics, Inc. (NTLA) stock, price quote and chart, trading and investing tools. Baixe Sinal de venda fotos no melhor site de banco de imagens, com milhões de fotos, imagens e figuras sem royalties e de alta qualidade premiu com preços acessíveis.
In depth view into NTLA (Intellia Therapeutics) stock including the latest price, news, dividend history, earnings information and financials.
Get breaking news and analysis on Intellia Therapeutics, Inc. (NTLA) stock, price quote and chart, trading and investing tools. Baixe Sinal de venda fotos no melhor site de banco de imagens, com milhões de fotos, imagens e figuras sem royalties e de alta qualidade premiu com preços acessíveis. Get instant access to a free live interactive chart for the Intellia Therapeutics Inc stock. You have the option to change the appearance of the charts by varying the time scale, chart type, zooming in to different sections and adding new studies or indicators such as RSI, MACD, EMA, Bollinger Bands, Fibonacci retracements and many more. 18/04/2016 · Founded in 2014, Intellia Therapeutics has taken in $89 million in funding compared to the $210 million in funding Editas Medicine (NASDAQ:EDIT) took in prior to their IPO. Intellia filed for an IPO last week to raise $50 million compared to the $94.4 million Editas Medicine raised in their recent IPO. 08/11/2019 · NTLA, Intellia Therapeutics - Stock quote performance, technical chart analysis, SmartSelect Ratings, Group Leaders and the latest company headlines Intellia Therapeutics (NTLA) - DEVELOPS THERAPEUTICS USING A BIOLOGICAL TOOL KNOWN AS CRISPR/CAS9 SYSTEM TO TREAT GENE-ASSOCIATED DISEASES. Cara Therapeutics A Cara Therapeutics Inc. foi fundada em 2004 e tem sede em Stamford, no Connecticut. Esta empresa de biotecnologia desenvolve e comercializa soluções farmacêuticas, sobretudo para alívio da dor do sistema nervoso periférico pela estimulação seletiva dos recetores opióides capa periféricos do corpo.
05/11/2019 · Intellia Therapeutics, Inc. engages in the development of gene editing-based therapies. It provides scientific expertise, clinical development, and intellectual property position to unlock broad therapeutic applications of CRISPR or Cas9 genome editing and develop a potential new drug class. Pros. I've been at Intellia for 3 years and although it may not be the same 50 person startup I joined, it's still a fun/great place to work. There is a constant effort to improve different programs (benefits, company culture, etc.) as we grow and there is an effort to listen to what employees have to say. Fundamental analysis data for Intellia Therapeutics Inc (NTLA), including price-earnings ratios and earnings per share, at Ally Invest. 10/01/2020 · What makes Intellia Therapeutics Fierce: Backed from the start by Novartis, which among all the Big Pharma companies in the top 10 seems to be one of the few that knows how to move fast when it finds something exciting, Intellia almost overnight found itself with a crossover group willing to pave the way into an IPO with a $70 million round.